Kevin Blackburn CCRC

I am consulting with The Conafay Group, a non-dilutive funding source using government agencies to support research. We form partnerships with federal, non-profit, academic, and other commercial entities. Our federal funding expertise includes: • Department of Defense • USAMRDC: U.S. Army Medical Research and Development Command • CDMRP: Congressionally Directed Medical Research Program • DTRA: Defense Threat Reduction Agency • MTEC: Medical Technology Enterprise Consortium • MCDC: Medical CBRN Defense Consortium • Department of Health and Human Services • NIH: National Institutes of Health • BARDA: Biomedical Advanced Research and Development Authority Other government funders of basic research through advanced development With 200+ years of combined experience, we’ve helped clients secure nearly $1B in non-dilutive funding and services since 2003. The Conafay Group helps clients implement tailored and dynamic government funding strategies for their biomedical research pipeline.

Clinical Holding Company

Lead U.S. and global business development strategy across preclinical and clinical portfolios. • Currently have a 30M+ pipeline and have a written award of 3M+ • Cultivate key client relationships in oncology, neurology, translational medicine, and toxicology to drive long-term partnerships. • Partner with executive leadership to identify market expansion opportunities and align R&D capabilities with client needs with special expertise in Neuropharmacology, DMPK, Toxicology, Bioanalysis, Translational Medicine, and Clinical Development.

Built a $30M+ pipeline, secured $3M+ in awarded business, and strengthened partnerships in oncology, neurology, toxicology, and translational medicine.

• Ranked #1 in revenue generation among BD professionals with less than 10 years’ tenure. • Secured 5 RFPs within the first six months; achieved $2M+ closed business in under a year. • Consistently led BD activity metrics and finished Top 4 of 13 global BD executives.

Led business development strategy for early phase clinical trials. Specialized in DMPK, bioanalysis, bioassays, and gene therapy.

Southern Star Research is an Australian Contract Research Organization (CRO). EARLY PHASE SPECIALISTS - Southern Star Research’s clinical team addresses and supports the needs of pharmaceutical, biotech and medical device companies in the early stages of clinical development. Secured 14 RFPs for $21.3M in 2022 Successfully developed and fostered relationships with key decision-makers by anticipating and identifying customer challenges and partnering with the operations team leader to provide solutions. Instrumental in expanding name recognition and brand awareness.

George Clinical, the Science CRO and the preeminent renal CRO in the world. Ranked #1 BDer by exceeding revenue goals by 120%, closing $18.5M in Phase I–III studies. Expanded client portfolio by 30+ accounts with over $100M in closing value.

Exceeded revenue goals by 120%, closing $18.5M in Phase I–III studies. Expanded client portfolio by 30+ accounts with over $100M in closing value.

Developing an innovative compound with a pivotal clinical trial (Phase 2/3) for a biologic orphan drug in late stage, systemic scleroderma scheduled for Q2 2019.

Specialty full service CRO. Led a “cutting-edge” business development team (9 full-time US and 1 EU member): $47,800,536 in team awards in 2016 and $315,896,238 in team proposals submitted in 2016

KCR U.S. is a wholly owned subsidiary of KCR. KCR is the original Central and Eastern European Contract Research Organization (CRO) Secured 17 RFPs for $12.7M by identifying and developing new business relationships while securing RFPs with the objective of achieving new business opportunities throughout the US.